Home » Stocks » CRSP

CRISPR Therapeutics AG (CRSP)

Stock Price: $166.58 USD -2.95 (-1.74%)
Updated Jan 27, 2021 11:37 AM EST - Market open
Market Cap 13.62B
Revenue (ttm) 77.37M
Net Income (ttm) -211.28M
Shares Out 70.14M
EPS (ttm) -3.39
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 27
Last Price $166.58
Previous Close $169.53
Change ($) -2.95
Change (%) -1.74%
Day's Open 161.83
Day's Range 155.28 - 168.59
Day's Volume 1,663,711
52-Week Range 33.68 - 210.04

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
The Motley Fool - 18 hours ago

If you're afraid of a pop, it's best to be prepared.

Other stocks mentioned: COUP, CRWD, FUTU, GH, GS, MKTX, SNOW
The Motley Fool - 3 days ago

With a nest egg this sizable, you'll need to find more than one place to put your money so it keeps growing.

Other stocks mentioned: EDIT, JNJ, SPY, VRTX, VTI
GuruFocus - 1 week ago

Among the public companies that made the BioSpace list of the top up and coming life sciences firms in 2019 and 2020, the majority have seen gains in their share prices. Given this metric, inv...

Other stocks mentioned: BEAM, EDIT, NTLA, SWTX
Zacks Investment Research - 1 week ago

CRISPR Therapeutics' (CRSP) lead gene-editing candidate CTX001, being developed for treating SCD and TDT, holds potential. It has a strong partner in Vertex.

The Motley Fool - 1 week ago

These companies offer some of the most innovative technologies in the life sciences industry.

Other stocks mentioned: VRTX
InvestorPlace - 1 week ago

Between these seven genetic editing pioneers, you have the widest exposure to the biggest scientific breakthrough of the century. The post 7 CRISPR Stocks for the Future of Medicine appeared f...

Other stocks mentioned: BEAM, CLLS, CLXT, EDIT, NTLA, SGMO
Forbes - 2 weeks ago

Gene editing has emerged as a promising biotech theme. The technology is used to insert, edit, or delete a gene from an organism's genome, helping to replace the defective genes responsible fo...

Other stocks mentioned: EDIT, NTLA
GuruFocus - 2 weeks ago

A leading portfolio manager recently told Bloomberg Television that gene-editing companies may turn out to be better investment opportunities than Tesla Inc. (NASDAQ:TSLA).

Other stocks mentioned: EDIT, NTLA
Investors Business Daily - 2 weeks ago

Intellia Therapeutics offered an update Thursday for its gene-editing programs, helping boost genetics stocks Crispr Therapeutics, Editas Medicine, Fate Therapeutics and Beam Therapeutics. The...

Other stocks mentioned: NTLA, EDIT
Zacks Investment Research - 2 weeks ago

Here we discuss three booming technological developments in the biotech sector, which can capture investor attention in 2021

Other stocks mentioned: ABBV, EDIT, NTLA, PFE, RHHBY, VRTX
The Motley Fool - 3 weeks ago

Berkshire's best days seem to be behind it, but this investing wiz could be the next Buffett.

Other stocks mentioned: ARKF, ARKG, ARKK, ARKQ, ARKW, NVTA, ROKU, SQ, TSLA
The Motley Fool - 4 weeks ago

The gene-editing stocks are being pulled down by a broader biotech sell-off.

Other stocks mentioned: EDIT, NTLA
Seeking Alpha - 1 month ago

Since the Nobel Prize in Chemistry was awarded to Jennifer Doudna and Emmanuelle Charpentier for their work on gene editing technology, CRISPR, related stocks have been red hot. CRISPR technol...

Zacks Investment Research - 1 month ago

Here we discuss some biotech stocks, which are up this year so far but might not be good additions to your portfolio.

Other stocks mentioned: DNLI, MCRB, NK, RCKT
InvestorPlace - 1 month ago

CRSP stock is rallying today as CRISPR Therapeutics and its gene-editing peers move into the spotlight. Here's what you should know.

The Motley Fool - 1 month ago

Here's how three nascent drugmakers could make 2021 a banner year for your portfolio.

Other stocks mentioned: ALXN, VRTX
The Motley Fool - 1 month ago

This gene-editing leader's current programs only reveal a hint of what it could become.

InvestorPlace - 1 month ago

It's a relief to know Covid-19 vaccines are on the way. But there are plenty of other great biotechs that have been overlooked in the market frenzy.

Other stocks mentioned: BNTX, DNLI, MRTX, NVAX, SGEN, ZLAB
The Motley Fool - 1 month ago

These disruptive biotech stocks could prove to be great investments in the long run.

Other stocks mentioned: VRTX
The Motley Fool - 1 month ago

The battle for beta thalassemia and sickle cell disease patients is heating up.

Other stocks mentioned: BLUE, VRTX
Seeking Alpha - 1 month ago

CRISPR Therapeutics and Vertex Pharmaceuticals released data on 10 patients treated with their investigational CRISPR/Cas9 gene-editing therapy, CTX001, showing durable response to treatment, ...

Zacks Investment Research - 1 month ago

In the Century of Biology, it pays to own the future of curing disease at the root.

Other stocks mentioned: EDIT, NTLA, SGMO, VRTX
The Motley Fool - 1 month ago

Analysts have been raising their price targets on the stock based on news about a treatment the biotech is developing in partnership with Vertex Pharmaceuticals.

Seeking Alpha - 1 month ago

CRISPR Therapeutics AG (CRSP) Phase 1/2 CTX001 Investor Update (Transcript)

InvestorPlace - 1 month ago

Listen in to hear how you can profit in 2021 and beyond

Other stocks mentioned: ARKG, BEAM, BEEM, EH, F, GIX, LAZR, LI, NIO, OAC, QS, TM, TSLA, VWAGY, XPEV
Zacks Investment Research - 1 month ago

Investors need to pay close attention to CRISPR Therapeutics (CRSP) stock based on the movements in the options market lately.

The Motley Fool - 1 month ago

One metric shows that decades of dominance treating diabetes has created unrivaled profitability.

Other stocks mentioned: BIIB, BNTX, EDIT, LLY, NVO, RHHBY, SNY
Zacks Investment Research - 1 month ago

CRISPR Therapeutics' (CRSP) gene-editing therapy, CTX001, shows sustained response to treatment in patients with transfusion-dependent beta thalassemia as well as sickle cell disease. Shares r...

Pulse2 - 1 month ago

The stock price of Crispr Therapeutics AG (NASDAQ: CRSP) has increased by 18.98% over the past week. This is why it happened.

GlobeNewsWire - 1 month ago

- Beta thalassemia: All seven patients were transfusion independent with 3 to 18 months of follow-up after CTX001 infusion -

Seeking Alpha - 1 month ago

CRISPR Therapeutics AG (CRSP) CEO Samarth Kulkarni at Piper Sandler 32nd Annual Virtual Healthcare Conference (Transcript)

Seeking Alpha - 1 month ago

Currently, value stocks are mostly value traps, while market leaders are expensive. We have to find diversification elsewhere. Genome editing is a space poised for innovation. The costs are de...

GlobeNewsWire - 1 month ago

ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Dec. 01, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced th...

Seeking Alpha - 1 month ago

Allogeneic cell therapies have a significant cost, convenience and efficiency advantage over autologous. Data from three of the leaders: Allogene, Atara and CRISPR are expected in the next 12-...

Other stocks mentioned: ALLO, ATRA, BMY, CLLS, GILD, NVS, PFE
GlobeNewsWire - 2 months ago

ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 24, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines...

The Motley Fool - 2 months ago

Innovative companies are trying to ensure that CRISPR Therapeutics' foothold in gene editing doesn't last forever.

InvestorPlace - 2 months ago

Even after rebounding in recent weeks, consider now (or any pullback) prime time to enter a long-term position in CRISPR stock. The post Volatility May Continue, But CRISPR Stock Remains a Buy...

InvestorPlace - 2 months ago

This Swiss biotechnology company works on the cutting edge of gene editing and Crispr stock is a play on future treatments. The post Crispr Stock Is Volatile, but Worth the Wait as a Buy-and-H...

Forbes - 2 months ago

Despite a large 3x rise since the March 23 lows of this year, at the current price of around $107 per share we believe CRISPR Therapeutics stock, a biotechnology gene editing company focused o...

GlobeNewsWire - 2 months ago

ZUG, Switzerland and CAMBRIDGE, Mass., Nov. 16, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines...

The Motley Fool - 2 months ago

Innovation might be worth the high risk up front investment.

Other stocks mentioned: ITCI
Investors Business Daily - 2 months ago

Crispr Therapeutics and Vertex Pharmaceuticals unveiled promising results for a gene-editing approach to blood diseases Wednesday. The news sent CRSP stock flying higher.

The Motley Fool - 2 months ago

CTX001 continues to help patients with transfusion-dependent beta thalassemia and sickle cell disease.

Other stocks mentioned: VRTX
GlobeNewsWire - 2 months ago

ZUG, Switzerland and CAMBRIDGE, Mass. and BOSTON, Nov. 04, 2020 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) and Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced da...

The Motley Fool - 2 months ago

Its approach to cell therapy is lucrative and immensely powerful for patients.

The Motley Fool - 2 months ago

These biotechs are fueling up for massive market launches.

Other stocks mentioned: ARWR
The Motley Fool - 2 months ago

The company flipped to a bottom-line loss for the period.

GlobeNewsWire - 2 months ago

-Reported positive top-line results from the Company's ongoing Phase 1 CARBON trial evaluating the safety and efficacy of CTX110™, targeting CD19+ B-cell malignancies-

InvestorPlace - 3 months ago

Most Nasdaq stocks have seen ups and downs this year. But these seven have weathered the pandemic well and are bound to climb higher soon.

Other stocks mentioned: AAPL, CTXS, MELI, PYPL, SGEN, TSLA
The Motley Fool - 3 months ago

Early signs of success with a revolutionary new type of cancer treatment make this biotech worth a closer look.

About CRSP

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious human diseases. It develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX00... [Read more...]

Industry
Biotechnology
IPO Date
Oct 19, 2016
CEO
Samarth Kulkarni
Employees
304
Stock Exchange
NASDAQ
Ticker Symbol
CRSP
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 18 analysts, the average rating for CRSP stock is "Buy." The 12-month stock price forecast is 146.56, which is a decrease of -12.02% from the latest price.

Price Target
$146.56
(-12.02% downside)
Analyst Consensus: Buy